To include your compound in the COVID-19 Resource Center, submit it here.

BMS's oral HCV combo under review in China

Bristol-Myers Squibb Co. (NYSE:BMY) presented data from an open-label Phase III trial evaluating a combination of its HCV drugs Daklinza daclatasvir plus Sunvepra

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE